1. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma;Ramachandran;J. Immunother. Cancer,2019
2. SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma [Conference presentation];D'Angelo,2021
3. Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors [Conference presentation];Hong,2020
4. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response;Robbins;Clin. Cancer Res.,2015
5. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers;Nagarsheth;Nat. Med.,2021